Current therapy guidelines for Waldenstrom's macroglobulinaemia
- 1 June 2016
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 29 (2), 194-205
- https://doi.org/10.1016/j.beha.2016.08.023
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Guidelines on the diagnosis and management of Waldenström macroglobulinaemiaBritish Journal of Haematology, 2014
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesMayo Clinic Proceedings, 2010
- Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's MacroglobulinemiaJournal of Clinical Oncology, 2009
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003